Category
Healthcare systems
How health systems are financed, organised and reformed, and what that means for the adoption of new technologies. Comparative where it is useful, specific where the detail matters.
284 articles in this topic.
Articles in this category

11/3/2026
Generic lenacapavir HIV prevention gets FDA tentative approval
Dr. Reddy's has FDA tentative approval for generic lenacapavir HIV prevention, priced at US$40 per person per year across 120 countries. #SyenzaNews #HIVprevention #MarketAccess
Read Article →
11/2/2026
PBS Strategic Agreements: What Government and Industry Told Patients Before the Next Deal
Australia's PBS strategic agreements with the medicines industry expire on 30 June 2027. At a 23 October webinar, the health department, GBMA and Medicines Australia explained what the deals cover, how patients can feed in, and where industry says they have fallen short on access. #SyenzaNews #MarketAccess #HTA #PBS #Australia
Read Article →
10/30/2026
Labor Department Finalizes PBM Fee Disclosure Rule for Large Self-Insured Plans
The US Department of Labor has finalized its PBM fee disclosure rule. From plan years beginning on or after 1 July 2027, PBMs must disclose rebates, spread compensation, copay claw-backs and per-drug net prices to large self-insured ERISA plans, report twice a year, and accept an annual audit by an auditor the plan chooses. EBSA estimates $818.4 million a year in transfers from PBMs to plans and participants. #SyenzaNews #PBM #DrugPricing #MarketAccess
Read Article →
10/30/2026
Lancet Authors Make the Case for an EU Medical Device Agency
Four authors writing in The Lancet Regional Health - Europe say the Commission's MDR and IVDR simplification proposal keeps the core flaw: notified bodies still decide, one by one, whether innovative devices reach the market. They argue for an EU medical device agency with binding powers over strategy, guidance and advice. #SyenzaNews #MedTech #MedicalDevices #MarketAccess
Read Article →
10/29/2026
Portugal Outpatient Medicine Spend Rises 7.9%, Led by Diabetes Drugs
Portugal's outpatient medicine bill rose 7.9% in January to August 2026. Antidiabetics drove nearly a third of the increase, and semaglutide spend rose 54.5%. #SyenzaNews #MarketAccess #HealthEconomics
Read Article →
10/28/2026
Individualised gene therapies for rare diseases: FDA draft guidance
The FDA's draft guidance lets sponsors add new patient-specific variants to one BLA without new trials, while CMS plans to broaden its gene therapy access model.
Read Article →
10/27/2026
Novartis core operating income rises, 2026 outlook raised
Novartis core operating income rose 10% at constant exchange rates in Q3 2026, and 2026 guidance for the measure was raised. #SyenzaNews #MarketAccess
Read Article →
10/26/2026
Antiretroviral Tender Awards Declared Invalid by Pretoria Court
A Pretoria court has declared invalid the antiretroviral tender awards for two items and ordered the health department to redo the split within 120 days. Cipla's review succeeded on all five grounds, while Hetero's challenge was dismissed with attorney-and-client costs. #SyenzaNews #SouthAfrica #HIV
Read Article →
10/13/2026
Health Security in Europe: Why Resilience Starts Before a Crisis
Health security in Europe is being redefined from emergency response to national resilience, and the EFPIA View argues it starts with funded health systems.
Read Article →
10/13/2026
Health Investment Returns: What Berlin’s Funding the Future Panel Argued
Ministers, development banks and industry at the World Health Summit argued that health investment returns should be measured in lives saved, jobs and tax revenue, not budget size. #SyenzaNews #HealthEconomics #MarketAccess
Read Article →
10/12/2026
The Strategic Health Economy: Why Finance Ministries Still See Health as a Cost
At the World Health Summit in Berlin, speakers from the European Commission, Japan, Africa, the Asian Development Bank and industry argued that health is a strategic economic asset, and asked how to persuade finance ministries. #SyenzaNews #HealthEconomics
Read Article →
10/8/2026
PhRMA’s GLOBE Drug Pricing Lawsuit Seeks to Block the Medicare Rule
PhRMA has sued HHS and CMS over the GLOBE rule, arguing the agency has no authority to tie Medicare Part B drug payments to the prices paid in 19 other countries. The complaint leans on the major questions doctrine and a statutory ban on quality-adjusted life years.
#SyenzaNews #MarketAccess #pharmaceuticals #healthcarepolicy #drugpricing
Read Article →


